180 related articles for article (PubMed ID: 31820529)
1. Assessment of rejection risk following subtherapeutic calcineurin inhibitor levels after pediatric heart transplantation.
Kerr SM; Jorgensen NW; Hong BJ; Friedland-Little JM; Albers EL; Newland DM; Law YM; Kemna MS
Pediatr Transplant; 2020 Feb; 24(1):e13616. PubMed ID: 31820529
[TBL] [Abstract][Full Text] [Related]
2. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibitor- and corticosteroid-free immunosuppression in pediatric heart transplant patients.
Sierra CM; Tan R; Eguchi J; Bailey L; Chinnock RE
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27658616
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
5. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
[TBL] [Abstract][Full Text] [Related]
6. Association of parental pretransplant psychosocial assessment with post-transplant morbidity in pediatric heart transplant recipients.
Stone D; Banerjee M; Dupuis J; Leleszi J; Allasio D; Singh TP
Pediatr Transplant; 2006 Aug; 10(5):602-7. PubMed ID: 16856997
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics.
Israni AK; Riad SM; Leduc R; Oetting WS; Guan W; Schladt D; Matas AJ; Jacobson PA;
Transpl Int; 2013 Oct; 26(10):982-9. PubMed ID: 23879408
[TBL] [Abstract][Full Text] [Related]
10. Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.
Bergh N; Gude E; Bartfay SE; K Andreassen A; Arora S; Dahlberg P; Dellgren G; Gullestad L; Gustafsson F; Karason K; Rådegran G; Bollano E; Andersson B
ESC Heart Fail; 2020 Apr; 7(2):567-576. PubMed ID: 32059083
[TBL] [Abstract][Full Text] [Related]
11. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
12. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
13. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
[TBL] [Abstract][Full Text] [Related]
14. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
15. Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation.
Vaughn GR; Jorgensen NW; Law YM; Albers EL; Hong BJ; Friedland-Little JM; Kemna MS
Pediatr Transplant; 2018 Feb; 22(1):. PubMed ID: 29222866
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure.
Groetzner J; Meiser B; Landwehr P; Buehse L; Mueller M; Kaczmarek I; Vogeser M; Daebritz S; Ueberfuhr P; Reichart B
Transplantation; 2004 Feb; 77(4):568-74. PubMed ID: 15084937
[TBL] [Abstract][Full Text] [Related]
17. Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation.
Celik S; Doesch AO; Konstandin MH; Kristen AV; Ammon K; Sack FU; Schnabel P; Katus HA; Dengler TJ
Transplant Proc; 2011 Jun; 43(5):1862-7. PubMed ID: 21693290
[TBL] [Abstract][Full Text] [Related]
18. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
20. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]